P274 COVID-associated invasive pulmonary aspergillosis (CAPA) — a case report

POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM: : COVID-associated pulmonary aspergillosis (CAPA) is a severe fungal infection with a high mortality rate. The incidence of CAPA is on the rise possibly due to the prescription of corticosteroids and tocilizumab two repurposed drugs used for treating SARS COV-2. Diagnosis is challenging due to the non-specific nature of symptoms. Voriconazole is the mainstay of therapy. We present a case of a 42-year-old male presenting with left hydro pneumothorax post recovery from COVID infection, and later succumbed to this complication. Patients developing pulmonary aspergillosis after short-term steroid therapy is uncommon. The possibility of aspergillosis in immunocompetent patients should be considered in those on systemic steroids and deteriorating pulmonary functions.